Federal Trade Policy and Evidence-Based Drug Pricing
 | Pharmaceutical provisions in American bilateral trade agreements with Australia and Korea can effect state and local govfernment programs that negotiate medicine prices for programs including Medicaid. PIJIP explains these provisions andidentifies pending legislation that would protect these state and local programs. |
 | Locally elected officials led by the National Legislative Association on Prescription Drug Prices Working Group on Trade have reached out to trade officials to warn of the dangers certain trade objectives pose to medicine affordability in the US. They have written House and Senate committees and the US Trade Representative, and have submitted testimony describing the problem. |
 | The Forum on Democracy and Trade and others have spoken out against trade policies that will limit states' rights to negotiate medicine prices through evidence bases drug pricing. |
 | Trade agreements are negotiated with at the federal level, yet state and local government laws and policies opposed by industries or foreign goverrnments can trigger retaliation. This page includes WTO panel reports and trade agreements language that addresses this federal/state interaction. |
Attribution for use of photos posted online under creative commons licenses: Photo of blue pills by Darren Hester. Photo of Massachusetts Statehouse by Eric Baetscher.
